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In the later stages of infection or after the host recovers, lymphocytes encoun- 
tering antigens of the infecting organism confer upon macrophages an enhanced 
capacity  to  kill  the  same  or  unrelated  pathogens  (1).  This  process  is  termed 
macrophage activation (2).  Over a  decade ago, antigen-stimulated  lymphocytes 
were  found  to  release  a  glycoprotein(s) (3)  that  enhanced  the  activity  of the 
hexose monosphosphate shunt in macrophages (4). Soon thereafter, supernatants 
from antigen- or mitogen-stimulated lymphocytes were shown to augment mac- 
rophage  antimicrobial  activity (5-9).  More  recently, it  was  demonstrated  that 
lymphoid supernatants increase the capacity of both murine (10-13) and human 
(14,  15) macrophages to secrete chemically reactive, incompletely reduced me- 
tabolites of molecular oxygen, including hydrogen peroxide. The capacities of 
macrophages to secrete hydrogen peroxide and to kill various microorganisms 
are closely correlated (10,  1 1).  In fact, reactive oxygen intermediates appear to 
mediate much (though not all [ 15,  16]) of the antimicrobial function of activated 
macrophages against such intracellular pathogens as Toxoplasma  gondii,  Trypano- 
soma cruzi, Leishmania, Candida sp., and mycobacteria (reviewed in reference 17). 
Thus, cell-mediated immunity to intracellular pathogens appears  to depend  in 
large part on the secretion by lymphocytes of a factor(s) that activates macrophage 
oxidative metabolism and antimicrobial activity. In this paper,  the lymphokine 
(LK) 1 meeting this description is called macrophage-activating factor (MAF). 
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The synthesis of MAF by lymphocytes in trace amounts, and its secretion even 
by cloned lymphoid populations  in  admixture  with  other  LK, have frustrated 
attempts to identify it physicochemically. One  hypothesis is  that  MAF  is inter- 
feron gamma (IFN3,). There is strong evidence that IFN3, is the LK that induces 
the expression of Ia or DR antigens on Macrophages (18,  19) and primes them 
for antitumor activity (20,  21).  Various  IFNs  stimulate  monocyte plasminogen 
activator release (22, 23) and Fc receptor expression (24, 25). However, none of 
these effects is known to be linked directly with enhanced antimicrobial activity. 
Partially  purified,  leukocyte-derived  IFNs  may  contain  other  LK.  Polydonal 
antibodies may neutralize not only IFN but the contaminants as well. Even proof 
that cloned, recombinant IFN can activate macrophages would not establish that 
lymphocytes  do  so  by  means  of  IFN.  For  all  these  reasons,  the  relationship 
between MAF and IFN has remained undefined. 
In this report, we made use of unpurified antigen- and mitogen-induced LK, 
partially  purified  lymphocyte-derived IFN3',  pure  IFN3,  produced  by bacteria 
containing the cloned human  gene (26),  and  a  monoclonal antibody that  neu- 
tralizes IFN3,.  This combination of reagents has permitted the identification of 
IFN3,  as  the  LK that  enhances  both  the  production  of hydrogen peroxide by 
human macrophages and their ability to kill an intracellular microbial pathogen. 
Materials and Methods 
Culture of Monocvtes.  Mononuclear leukocytes (MNL) were isolated from the venous 
blood of normal adult donors as described (14,  27).  13-mm diam glass coverslips were 
pretreated for 1 wk with 50% HNO3 before they were cleaned in ethanol as detailed (27). 
For experiments with  H202  release,  1 X  10  6  MNL  suspended  in  0.1  ml  RPMI-1640 
containing 100 U/ml penicillin,  100 #g/m] streptomycin and 25% fresh-frozen human 
serum (R-HuS) were plated per coverslip. After 2 h, the coverslips were rinsed three times 
in warm Eagle's minimum essential medium and transferred to 16-mm diam wells in 24- 
well trays (Costar Data Packaging, Cambridge, MA) in 0.3 ml R-HuS. The medium was 
replaced the following day (day 1), on day 3, and every 2-3 d thereafter. For experiments 
with T. go~tdii, 12-mm diam coverslips received 1.5 x  106 MNL in R-HuS containing 20% 
heat-inactivated human serum (Sabin-Feldman dye test-negative), and were cultured in 
groups of three coverslips per 35-mm diam plastic petri dish. Cultures were rinsed after 
2 h, and given fresh medium on day 1 and every third day thereafter. 
Hydrogen Peroxide Secretiot~.  Secretion  of H~O~ in  response  to  100  ng/ml  phorbol 
myristate acetate (PMA) (Consolidated Midlands Co., Brewster, NY) was measured by the 
fluorescent scopo]etin assay as described (27). The initial concentration of scopoletin was 
selected so that <50%  was oxidized. Six coverslips were used per data point: three for 
peroxide secretion and three to measure adherent cell protein by the method of Lowry 
et al.  (28),  with bovine serum albumin as the standard.  Results were expressed as nmol 
H,~O., per mg adherent cell protein. 
Antitoxoplasma Activity.  One  million  RH strain  T. gondii trophozoites obtained from 
infected mouse peritoneal exudates (29) were added  to each  35-mm dish for 30  rain. 
Uningested organisms were removed by washing, and coverslips were then cultured in 
standard  medium  (without  added  lymphocyte products).  At  4  h  and  18-20  h  after 
infection, replicate coverslips were fixed, stained, and scored microscopically for number 
of toxoplasmas per vacuole and per 100 macrophages (16, 29). 
LK m~d IFN Preparatio~s.  Buff), coats from 87  U  of blood were pooled at the New 
York Blood Center, and incubated for 48 h in serum-free RPMI-1640 containing 1 rag/ 
ml human albumin, 5 ng/ml mezerein, and 30 ~g/ml lentil lectin. At the concentrations 
added to monocytes, mezerein and lentil lectin or supernatants containing them did not 
themselves trigger H20~ release. Some of these supernatants were enriched for IFNy by 672  INTERFERON-7 AS  MACROPHAGE-ACTIVATING FACTOR 
sequential affinity chromatography to a specific activity of 1 x  106 antiviral U/ml; these 
are designated  MLL-IFN%  Details of the purification will be furnished elsewhere (M. 
Wiebe, M. Chang et al.,  manuscript in preparation). Another preparation, termed SEA- 
IFN3,, was obtained by stimulating buffy coat cells with staphylococcal enterotoxin A and 
purifying the supernatant by sequential column chromatography to a specific activity of 
1 x  107 U/mg protein, as described (references 30, 31, and B. Y. Rubin et al., manuscript 
in preparation). In addition, supernatants were collected from MNL cultures stimulated 
for 48 h with concanavalin A or toxoplasma lysate as reported previously (15).  Control 
LK were obtained by adding concanavalin A  to MNL cultures at the end of the 48-h 
incubation or by adding toxoplasma antigen at the outset of culture of MNL from Sabin- 
Feldman dye test-negative donors (15). Recombinant IFN3, synthesized by E. coli  (26) was 
provided by Genentech, Inc., South San Francisco, CA. The lot used, which gave a single 
band on analytical polyacrylamide gel electrophoresis (personal communication, Dr. Sang- 
He Lee), had a specific activity of 6  X  105 U/mg.  For consistency, we have arbitrarily 
expressed all antiviral titers in this paper according to unitage of assays performed by one 
of us (B. R.) in comparison to a laboratory standard, using a cytopathic effect inhibition 
assay with vesicular stomatitis virus in WISH (HeLa) cells (32).  It should be noted that 
different  antiviral  activities  were  recorded  for  some  of these  preparations  in  other 
laboratories. 
Antibodies "to IFN.  Monoclonal IgGt antibody GIF-1 neutralizes human IFN3, but not 
IFNc~ or  IFNI3 (31).  The GIF-1  hybridoma supernatant  used  here had a  neutralizing 
activity of 5,000  U/ml.  Sheep  globulins  to  human  IFNc~ and  to  human  IFN3  were 
National Institutes of Health (NIH) reference preparations GO 26-502-568 and GO 28- 
501-568, respectively. Test media were preincubated with antibody for 30-90 rain before 
use. Percent inhibition of peroxide-releasing capacity was calculated as 100(1-[PL~+A--PM] 
/[PLK--PM]), where P  =  nmol  H202/mg cell protein after treatment  of monocytes as 
indicated by the  subscripts (LK =  lymphokine or IFN3,,  A  =  antibody, M  =  medium 
control). 
ResuLts 
Elimination  by  Mo~oclonc~l Anti-IFN3,  Antibody  of the  Ability  of Unfractionated 
Lymphoid Supernatants to Enhance Peroxide Release  from Human Macrophages.  The 
15 experiments summarized in Table I are in accord with previous observations 
on  the  capacity of lymphoid supernatants  generated with  concanavalin A  (14, 
15)  or  toxoplasma  antigen  (15)  to  enhance  the  peroxide-releasing capacity of 
human  macrophages.  Similar results were seen with supernatants  of buffy coat 
cells pooled from multiple blood donors and exposed to lentil lectin and mezer- 
ein.  As  expected (33-35),  these supernatants  all contained substantial  titers of 
IFN'y (Table I).  IFN~ and IFN/3 could not be detected. To determine whether 
the stimulatory activity in  these  unfractionated supernatants  could be ascribed 
to their content of IFN"y, we made  use of a  monoclonal antibody (GIF-1) that 
neutralizes IFN-y but has no detectable effect on IFN0~ or IFNI3 (30). In 8 of 12 
experiments,  GIF-1  antibody  removed all  stimulatory activity from the  super- 
natants.  In  the remaining four experiments it was partially effective. Complete 
inhibition was seen with six of the seven LK preparations studied. 
To  rule  out  the  possibility  that  GIF-1  was  toxic,  we  added  the  antibody  to 
monocytes for 3 d beginning on day 1 of culture. When tested on days 2, 3, and 
4, these monocytes released  107%,  119%, and  113% as much peroxide as those 
cultured in  medium  alone (the latter released  529 +  13  [day 2], 420  +  7  [day 
3], and 630 -+ 70 [day 4] nmol/mg cell protein). This demonstrated the lack of 
direct  suppressive  effects  of antibody  GIF-1,  and  further  suggested  that  the NATHAN  ET  AL.  673 
TABLE  I 
Stimulation of Human Macrophage Peroxide-releasing Capacity by Unfractionated Lymphoid 
Supernatants: Prevention by Monoclonal Antibody to IFN'y 
Concen-  H20~ release by  H~O2 release,  Inhibition  by 
Stimuli for LK  1FN3,  tration  experimental*/  monoclonal 
production*  titer  LK-treated cells*  IFN~, used  control  a cells  antibody  ! 
U/ml  U/ml  nmol/mg  protein~60  % 
min 
Lentil lectin + 
mezerein 
Prep.  1  100  1-10  321,520, 529,  1.5, 1.8, 2.9,  141,311 ~ 
657, 6964  2.9,  12.0  ~ 
Prep.  2  1,000  100  1094  1.7  170 
Concanavalin A 
Prep.  1  1,000  67-100  339,  1052  2.7, 3.1  85, 89 
Prep. 2  3,000  100-300  368,912  2.3, 5.1  49,  104 
Prep. 3  1,500  100  511  4.7  105 
Control**  0  0  172,305,394  0.8, 0.9,  1.2  ND  ~ 
Toxoplasma anti- 
gen 
Prep.  1  6,000  400-600  514,919, 1022  2.3, 4.5, 4.8  78, 113, 146 
Prep. 2  2,000  134  529  4.9  95 
Control  H  0  0  157, 189  1.2, 1.2  ND 
Overall means -4-_ 
SEM (N):  666 _ 67 (15)  3.8 -+ 0.6 (15)  124_ 19 (12) 
* MNL from individual donors (for concanavalin A or toxoplasma antigen preparations)  or buffy 
coat cells pooled  from 87 donors (lentil lectin +  mezerein)  were incubated with the indicated 
stimuli and the supernatants collected as described in Materials and Methods. Prep., preparations 
made with different cells on different days. Different batches of toxoplasma lysate were used for 
the two antigen-stimulated  supernatants. 
Human macrophages  were exposed to the indicated concentration of LK for 3 d beginning on 
the 3rd to 12th d of culture, washed, and stimulated with PMA to measure H202 release. 
Control cells were tested in parallel with those in note *, except that LK was not added. 
I Antibody GIF-1  used at 60-600 U/ml of neutralizing capacity for antiviral activity. Inhibition 
calculated as described in Materials and Methods. 
Values for individual experiments performed on different days or with different donors' macro- 
phages, each in triplicate for both H~O2 release and adherent cell protein. SEM for H20~ release 
by triplicates averaged 8.6% of the mean for individual experiments. 
** MNL  received  concanavalin A just before  harvesting the  supernatant, which  was  added  to 
macrophages at a 10-fold dilution. 
** Not tested. 
Supernatants from MNL of Sabin-Feldman  dye test-negative donors incubated with toxoplasma 
antigen were used at a 10% concentration  on macrophages. 
elevated H202-releasing capacity typically observed over the first 3-4 d of culture 
of adherent MNL may not be sustained by IFN3, from contaminating T  cells. 
In  three  experiments,  incubation of macrophages  in  supernatant plus  anti- 
IFN3, antibody resulted in H202-releasing capacity substantially lower than that 
of macrophages incubated in medium alone (inhibition >140%,  Table I).  This 
suggested  that  lymphoid supernatants may contain factors  suppressing macro- 
phage oxidative metabolism. This possibility was also raised by the dose-response 
profile shown in Fig.  1, in which 30% by volume of unfractionated LK was much 
less stimulatory than 1%. 
On  the average, adherent cell protein was  1.7  _  0.3  times greater after  3  d 674  INTERFERON-y  AS  MACROPHAGE-ACTIVATING  FACTOR 
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FIGURE  1.  Enhancement of macrophage peroxide-releasing  capacity by three IFN"r-contain- 
ing preparations and its prevention by monoclonal anti-IFN~' antibody.  Human macrophages 
were exposed  to the indicated  concentrations of IFN~ on days 4-7 of culture, washed, and 
stimulated  with PMA to measure  H20~ release.  An unpurified supernatant from buffy coat 
cells stimulated  with mezerein and lentil lectin (solid triangles) had 102 U/ml antiviral activity. 
A fraction  obtained from this supernatant (solid circles) had an antiviral activity of 104 U/ml 
or  t  x  10  ~ U/rag protein.  An  independently purified  preparation  from buffy coat cells 
stimulated  with staphylococcal enterotoxin A (solid squares) had an activity of 6 x  103 U/ml 
or 1 X 107 U/mg protein. The open symbols are results with the corresponding preparations 
exposed  to  120-350 neutralizing  U/ml of monoclonal anti-IFN~ antibody.  An equivalent 
amount of monoclonal antibody to a mouse H2 antigen (the kind gift of Dr. R. Steinman, The 
Rockefeller  University) had no effect (not shown). Means _ SEM for triplicates. 
incubation  of macrophages  in the  lymphoid supernatants  than in control media 
(n =  15).  Neither the elevations nor the reductions in adherent cell protein seen 
in  individual  experiments  were  consistently  affected  by monoclonal  anti-IFN'y 
antibody (data not shown). 
Effects of Partially  Purified  IFNy.  The  foregoing  experiments  implied  that 
IFN3, was the sole factor in the mitogen- or antigen-induced  lymphoid superna- 
tants tested that could enhance human  macrophage peroxide-releasing  capacity. 
If so, then native IFNy should have MAF activity. The results of 13 experiments 
with two independently derived preparations enriched in IFN~, are summarized NATHAN  ET  AL.  675 
in Table I I. On the average, I F N-r-rich fractions enhanced macrophage peroxide- 
releasing capacity 8.8-fold. Peroxide released by IFN~,-treated macrophages on 
days 7-9  sometimes exceeded that secreted by samples of the same monocytes 
on day 0. Monoclonal anti-IFN'r antibody inhibited IFN~,-mediated enhancement 
of  macrophage  peroxide-releasing  capacity  by  an  average  of  97%  in  seven 
experiments (Table II). In two titrations of preparation SEA-IFN-r (Fig. 1), 50% 
of  maximal  stimulation  of  macrophage  peroxide-releasing  capacity  followed 
incubation in 0.4 and  1.3 antiviral U/ml, and peak effects were seen at 30 and 
100  U/ml. 
Peroxide-releasing capacity usually (but  not invariably) peaked on  the third 
day of exposure to partially purified IFN% and thereafter declined somewhat, 
despite replenishment with fresh IFN% However, peroxide releasing-capacity of 
cells continuously exposed to IFN7 remained markedly elevated for at least 5 d, 
the longest period tested.  For example,  macrophages  treated with IFN~, from 
days 5-8 released  1,479  +  124 nmol/mg protein/60 min, compared to 393  _+ 
20 for controls. After 2 more days in IFN% peroxide secretory capacity fell to 
652  +  53,  compared  to  101  _+  25  for the controls.  However, when IFN7  was 
removed on day 8, secretion on day 11  fell to 23 _+ 4, compared with 12 +  2 in 
the controls.  Thus, the enhancing effect of partially purified IFN~, on  macro- 
phage  peroxide  release  was  reversible.  These  kinetics  closely  parallel  those 
reported earlier for unfractionated lymphoid supernatants (14). 
On the average, cultures incubated in IFN~,-rich fractions contained 1.5 +  0.3 
times as much adherent cell protein as those in medium alone (n =  13). This was 
unaffected by the antibody (not shown). 
Effects ofRecombina nt IFN'y.  To establish conclusively that IFN3, could activate 
niacrophages  for  enhanced  hydrogen  peroxide  release,  and  to  evaluate  the 
possible contribution of other lymphoid cell products that might copurify with 
TABLE II 
Stimulation  of Human Macrophage Peroxide-releasing Capacity by Partially Purified Native 
IFN'y: Prevention by Monoclonal Antibody to IFN'y 
H~O~ release by,  H202 release  Specific ac-  Concen-  IFN-treated cells 
Preparation  tivity  (U/  tration  (nmol/mg pro-  experimental* 
mg protein)  IFN~,  used  tein/60 min)  control  i cells 
Inhibition 
by mono- 
clonalanti- 
body  ! 
MLL-IFN',/**  1 X 106 
SEA-IFN3  ,~  1 X 10  7 
Overall means + 
SEM (n): 
U/ml 
10-242 
30-300 
% 
392,482,706,  2.0, 6.8, 7.1, 12.7  ~  102,  1241 
12261 
211,367,381,  2.0, 3.5, 5.3, 6.5,  41,  80,  103, 
652, 1168,  8.9, 11.4, 15.1,  108, 122 
1236, 1479,  24.5, 435 
1549, 2102 
919 _  155 (13)  8.8 _  1.8 (12)  M  97 _+ 10 (7) 
,0ll See Table I. SEM for H202 release by triplicate cultures averaged 9.5% of the mean in individual 
experiments. 
** LK induced with mezerein + lentil lectin and fractionated as described in Materials  and Methods. 
** LK induced with staphylococcal  enterotoxin A and fractionated as described in Materials and 
Methods. 
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IFNy, we next tested the effects of pure IFNy produced by bacteria transformed 
with the cloned buman gene for this LK. The potent MAF activity of recombinant 
IFN'y is illustrated for three independent titrations in  Fig.  2.  The positions of 
the three dose-response curves varied considerably. Half-maximal stimulation of 
macrophage peroxide-releasing capacity followed 3 d of exposure to 0.009, 0.14, 
and  1.3  U/ml of IFNT, with peak responses at 0.3,  10, and  1000  U/ml. The 
variability in the dose-response curves might be due in part to the use of different 
donors for the macrophages and the serum in each experiment. Another possible 
contributory factor is the fact that the time to peak response varied from 2 d of 
exposure (not shown) to as long as 4  d  (Fig.  3).  With continuous exposure to 
IFN% peroxide-releasing capacity remained elevated for at  least 6  d, but fell 
toward baseline within 3 d of removing the recombinant IFN'r (Fig. 3), as already 
noted  for  native  IFN%  In  the experiment illustrated  in  Fig.  3,  some of the 
macrophages were exposed to 100 U/ml of IFN7 for 10 min on day 6 of culture, 
extensively washed to remove IFNy, and then cultured in standard medium for 
3  more days. Their peroxide-releasing capacity was at least as great as that of 
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FIGURE  2.  Enhancement of macrophage peroxide-releasing capacity by pure,  recombinant 
1FN3,.  Two  experiments are  shown  in  which  macrophages  were  exposed  to  the  indicated 
concentrations of IFNy on days 6-9 (open circles and triangles) and one experiment in which 
exposure  was  from  days  5-8  of culture  (open  squares).  The  dashed  line  (solid  triangles) 
indicates results in the presence of monoclonal antibody to native IFNy added at (from left to 
right) 3,  10, or  I00 times the neutralizing activity for the indicated concentration of native 
]FN7. Means of triplicates are indicated. SEMs averaged 13% of the mean. NATHAN  ET  AL.  677 
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FIGURE 3.  Kinetics of response to recombinant 1FNT. Macrophages on day 6 of culture were 
incubated in standard  medium  (solid circles) or  100  U/ml  of IFN7  (open  circles) for  the 
indicated times before assay of H20~ release. Fresh medium of the same type was added on 
day 8 or 9  for cells assayed on days  11  or  12, respectively. The dashed line indicates results 
for cells which were removed from IFN7 on day 9, washed four times in standard medium, 
then incubated in the latter for 3 d before assay. The open triangle indicates cells which were 
pulsed with  100  U/ml  IFN7  for  10  min on  day  6,  washed  four  times,  and incubated in 
standard medium until assay on day 9. Means +  SEM of triplicates. 
cells exposed continuously to 100 U/ml IFN~, for the entire 3-d period. Results 
were similar in a second experiment using a 2-h pulse. 
In contrast to the results with native  IFNT,  monoclonal antibody GIF-1  had 
no inhibitory effect on the MAF activity of recombinant IFNT. This is illustrated 
in Fig. 2 with antibody concentrations ranging from 3 to  100 times the amount 
required to neutralize an equivalent antiviral  activity of native IFNT. Antibody 
GIF-1 also failed to inhibit the antiviral activity of recombinant  IFN3, (data not 
shown). 
The remarkable potency of recombinant IFN7 compared with,native IFN7 in 
some  experiments  raised  the  possibility  that  the  former  might  contain  a  co- 678  INTERFERON-3,  AS  MACROPHAGE-ACTIVATING FACTOR 
stimulator or the latter might contain a suppressor of MAF activity. To test these 
possibilities,  mixing  experiments  were  carried  out  as  shown  in  Table  III.  An 
effective but  suboptimal  dose  of recombinant  IFN3,  did  not  give  greater  than 
additive effects when combined with a suboptimal but effective dose of the native 
product.  An  optimal  dose  of  native  IFN3,,  when  neutralized  by  monoclonal 
antibody and added to recombinant IFN3,, did not give less than additive effects. 
Thus, neither costimulator nor suppressor factors could be detected by mixing. 
Secretion  of hydrogen  peroxide by macrophages was undetectable  or barely 
detectable  after  incubation  in  either  native  or  recombinant  IFN3,,  unless  a 
secretagogue such as PMA was added (data not shown). 
hTduction  of Antitoxoplasma  Activity,.  The  above experiments  established  that 
IFN3, enhances the oxidative metabolism of human macrophages. We next tested 
whether  IFN~ also augments the  antimicrobial activity of macrophages against 
an intracellular pathogen--the  cardinal criterion  for macrophage activation. As 
a  test organism, we used the protozoan, T. gondii.  The killing of this parasite by 
murine  macrophages  is  closely  related  to  their  capacity  to  secrete  hydrogen 
peroxide (1 1) and is mediated largely by oxidative mechanisms (1 1,  29),  but to 
some extent by oxygen-independent processes as well (16,  36). 
As shown  in  Fig.  4,  unstimulated  human  macrophages cultured  for  13-23  d 
before  infection  killed  >5%  of  ingested  toxoplasmas  in  the  first  4  h,  and 
supported intracellular replication (5.5 toxoplasmas/vacuole at 20 h). In contrast, 
when  the  cells  were  preincubated  for  3  d  with  unfractionated  mitogen-  or 
TABLE  Ill 
Evide~,ce Against a Suppressor  Factor in Partially Purified IFN3, or a Costimulator 
in Recombinal~t IFN3'* 
Predicted value 
H~O2, nmol/mg  for additive ef-  SEA-I  FN3,*  Recom.§  Aby|  protein/60 min  fects  ~ 
U/ml  U/ml  U/ml 
0  0  0  15_+ 11"* 
6  0  0  178 +  16 
30  0  0  367 _+ 16 
30  0  100  85 _+ 8 
0  0.1  0  139 _+ 28 
0  0.3  0  313 _  11 
0  0.3  3  313_+ 11 
0  1.0  0  332 + 8 
0  1.0  100  320 _+ 9 
6  0.1  0  199 _+ 13 
30  0.3  100  448 _+ 12 
30  1.0  100  478 _+ 8 
302 
383 
390 
* Macrophages were treated with IFN3, from days 6-9 of culture. 
* Partially purified, native IFN'y elicited with staphylococcal enterotoxin  A (see Table 
II). 
§ Recombinant IFN3,. 
I Monoclonal antibody G|F-I (does not neutralize recombinant IFN3,). 
([SEA-IFN3" + Aby]'- 15) + (Recom. -  15) +  15, where 15 is the value in medium 
alone. 
** Means --- SEM for triplicates. LK 
none 
II 
Con A 
II 
II 
II 
toxo 
II 
II 
II 
SEA 
II 
Recom. 
Aby 
anti -T 
anti-T 
anti -~ 
anti -/3 
anti-T 
anti -~x 
anti-/3 
anti -"f 
No. 
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FIC;URE 4.  Toxoplasmacidal activity of macrophages incubated in lymphokine (LK) prepa- 
rations with or without antibody to the indicated types of IFN. Incubations were in 100-300 
U/ml IFNy for 2-3 d beginning on days 13-23 of culture. Monoclonal  anti-IFN3, antibody 
was used at 300-600  neutralizing U/ml. Anti-IFNa and anti-IFN# antibodies were used at 
600 neutralizing U/ml. Unpurified LK were induced with concanavalin A (Con A) or toxo- 
plasma antigen (toxo). Partially purified native IFN3~ preparation SEA-IFN3"  had an activity  of 
l0  T U/mg protein. Recom., recombinant IFN3'. Means + SEM for the indicated number of 
experiments. 
antigen-induced LK or partially purified native IFN% they killed 38-60% of the 
initially ingested parasites within 4  h, and inhibited the replication of surviving 
organisms  (1.8-1.9  parasites/vacuole  at  20  h).  The  induction  of antiparasitic 
activity was abrogated  by treatment of the  unfractionated supernatants  or the 
partially  purified  IFN3'  with  monoclonal  anti-IFN3,  antibody,  but  not  with 
polyclonal sheep antibodies against human IFN~ or IFN/3 (Fig. 4).  Direct expo- 
sure to  10%  concanavalin  A-induced LK or to  300  U/ml  of partially purified 
native IFNy for t  h at 37 ° C did not affect the ability of toxoplasmas to survive 
and  replicate  when  subsequently  ingested by  unstimulated macrophages  (data 
not shown). 
Pure, recombinant IFN3, also markedly enhanced macrophage antitoxoplasma 
activity (Fig. 4) in a dose-dependent manner (Fig. 5). In the experiment illustrated 
in Fig. 5, macrophages that had been in culture for 13 d were exposed to IFN3, 
for  3  more  days  before  challenge  with  the  parasite.  Under  these  conditions, 
toxoplasmacidal  activity was  evident after  treatment  with  as  little  as  1  U/ml 
IFN3,.  Addition of 300  U/ml of recombinant IFN3' had no effect when it was 
added after infection of the macrophages (not shown). 
As with enhancement of peroxide-releasing capacity, there was variability in 
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FIGURE  5.  Effect of the concentration of recombinant IFNy on the toxoplasmacidal (solid 
circles) and toxoplasmastatic (open triangles) activity of human macrophages after 3 d exposure 
to IFN'r beginning on day 13 of culture. 
toxoplasmacidal activity. Peak activity was seen from 2-3 d after adding IFNy. 
Fig. 6 summarizes three such experiments. 
The effects of recombinant IFN3, were less dramatic when IFNy was added 
from  the  outset  of culture  (day  0)  to  monocytes that  were  challenged  with 
toxoplasmas on day 2.  In this case, the untreated controls, which could release 
copious H20~, killed 23% of ingested organisms by 4 h and limited the replication 
of the remainder to 2.0 per vacuole by 20 h. Monocytes treated from days 0 to 
2 with  100  U/ml IFNy killed 42%  of the organisms at 4  h  and displayed  1.4 
toxoplasmas/vacuole at 20 h. 
Effects  of IFNy  on  Cell  Shape.  Decreased  spreading  of human  monocytes 
incubated in IFNa or IFNfl has been attributed to inhibition of their maturation 
into macrophages (37, 38). We examined the effects of applying IFNy-containing 
media to cells that had already differentiated into macrophages.  Macrophages 
incubated in  control medium were usually bipolar,  multipolar,  or fan-shaped, 
with flat nuclear regions that were dark by phase-contrast microscopy (Fig. 7 a). 
In  unfractionated lymphoid supernatants or in partially purified native IFNy, 
the  cells  tended  to  spread  in  a  more  disklike  fashion  and  often  had  highly 
rounded, refractile nuclear regions (Fig.  7 b). Addition of monoclonal anti-IFNy 
forestalled these shape changes (Fig.  7 c). The same shape changes were seen 
after prolonged exposure to recombinant IFNy (Fig.  7 d), but were not always 
evident by the time peroxide-releasing capacity was elevated. Thus, the morpho- NATHAN  ET  AL.  681 
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logic alterations did not appear to be necessary for enhanced peroxide-releasing 
capacity. 
Discussion 
We conclude that IFN7 is a potent activator of human macrophage oxidative 
metabolism and antimicrobial activity. Under the conditions tested, the only such 
activator consistently detected in the medium of antigen- or mitogen-stimulated 
human leukocytes was IFN3'. IFN7 is the first secretory product ofT iymphocytes 
(33, 34, 39, 40) of known structure (41, 42). Thus it is of special interest that it 
capacitates macrophages to release a microbicidal product (H202) whose chemical 
composition is also known. 
IFN-),  is  the  LK  for which the  most  sensitive bioassay is  available,  namely, 
induction of antiviral resistance. With recombinant IFN% activation of macro- 
phage peroxide-releasing capacity was stimulated to 50% of the maximal value 
with  a  geometric  mean  concentration  of 0.1  antiviral  U/ml.  Assuming that 
recombinant IFN7 is a nonglycosylated dimer of 34,292  daltons, then the 50% 
maximally effective concentration of the preparation used here can be estimated 
at 0.4-63 picomolar (geometric mean, 6 pM). The remarkable sensitivity of the 
oxidative metabolism of human macrophages to enhancement by IFN3, suggests 
that macrophage activation may be one of the primary physiologic functions of 
this LK. 
It is now unarguable that more than one LK activity (as defined by effects on 682  INTERFERON--y  AS  MACROPHAGE-ACTIVAT1NG FACTOR 
FIGURE 7.  Morphology  of IFNT-treated macrophages  by  phase  contrast microscopy.  A, 
control cells in standard medium on day 8. B, macrophages exposed from days 5-8 to partially 
purified native IFNT. C, same as B but a4so exposed to monoclonal antibody against IFN3,. D, 
treated from days 6-12 with 100 U/ml recombinant IFN3,. 
different target cells) can be ascribed to the same molecule. Thus, IFN3, induces 
antiviral activity in a  variety of cell  types and enhances the capacity of macro- 
phages to secrete H202 and to kill toxoplasmas. In addition, it is now clear that 
a single LK can cause pleiotropic effects in the same cell population. For example, 
the recombinant IFN3, used in our studies has also been reported to enhance the 
expression  of DR  antigens (19)  and  Fc  receptors  (25)  on  monocytes, and  to 
activate monocytes to kill tumor cells (43). 
Four qualifications require emphasis. First, the term "MAF" has been applied 
to factors that induce a variety of physiologic changes in macrophages. We have 
used the  term  in a  restricted sense,  and our results do  not bear on the issue 
whether MAF as defined in other ways or in other species is IFN7 (reviewed in 
reference 21).  Second, our studies are fully compatible with the possibility that 
there may be other factors besides IFN3, that can induce the same changes in 
macrophages as  described  here.  IFNa,  a  product  of non-T  leukocytes, is  of 
special interest in this regard (C.  Nathan, H. Murray, B. Rubin, and M. Wiebe, 
unpublished observations). Our experiments do suggest that other MAFs were 
either not consistently present in active amounts in the lymphoid supernatants 
we studied, or if present, were masked by inhibitors or dependent on IFN3, in 
order  to activate macrophages.  Third,  as already noted,  the  biochemical and 
functional changes we measured in macrophages in response to IFN3, are only a 
few of an unknown number of alterations induced in the same cells by the same NATHAN  ET  AL.  683 
molecule. Experiments are in  progress to determine whether the lymphokine 
that enhances oxygen-independent antimicrobial activity in human macrophages 
(15, 16) may also be IFN% Finally, we have not formally excluded the possibility 
that the effects of IFN3, on macrophages could have been mediated by another 
type of cell contaminating the cultures. However, results were similar whether 
IFN~, was added starting on the 3rd through the 23rd day of culture. In most 
of  these  cultures,  no  cells  other  than  macrophages  could  be  identified  by 
morphologic criteria. 
Neutralization of MAF activity in crude lymphoid supernatants by the mono- 
clonal anti-IFN~, antibody was strong evidence that MAF was IFN%  However, 
the epitopes recognized by monoclonal antibodies may sometimes be shared by 
seemingly unrelated proteins (44).  Accordingly, it was necessary to determine 
directly whether native, leukocyte-derived IFN~ had MAF activity. Using two 
independent protocols  for  induction  and  partial  purification  of IFN%  MAF 
activity was readily demonstrated, was enriched to at least the same degree as 
antiviral activity, and was again neutralized by monoclonal anti-IFN~, antibody. 
Nonetheless,  these  preparations  of IFN"r  were  not  pure,  and  the  possibility 
remained  that  a  contaminant  contributed  to  MAF  activity.  For  a  definitive 
answer, we turned to a preparation in which IFN~, was the only human protein 
and probably the only protein, namely, IFN~, purified to apparent homogeneity 
from bacteria transformed with the cloned gene for human IFN3,.  This prepa- 
ration displayed especially potent MAF activity. The time required for macro, 
phages to display an optimal response to recombinant IFN~, varied from 2-4 d. 
Exposures to  IFN~' as brief as  10-120  min  led to  substantial  activation when 
macrophages were tested 3  d  later.  After 3  d  of exposure to  IFN%  peroxide 
secretory capacity fell to barely detectable levels when IFN~, was removed, but 
was elevated for at least 6 d when IFN~, remained. 
Monoclonal antibody GIF-1  neutralized both  the antiviral and macrophage- 
activating effects of native IFN~,,  yet neutralized neither of these effects of the 
recombinant bacterial product. There are believed to be two carbohydrate chains 
on native IFN7 (26, 41, 42) and none on the recombinant product. It is possible 
that the carbohydrate groups  contribute to the epitope seen by the antibody. 
These carbohydrates are not necessary for the expression of at least some of the 
antiviral (45) or MAF activity of IFN% However, the carbohydrate moieties may 
border a  domain necessary for IFN~, activity, such as a  receptor-binding site. 
The antibody might interfere with  the function of this domain by steric hin- 
drance. 
Recombinant IFN~, was usually considerably more potent than the equivalent 
concentration of native IFN'y, based on antiviral activity. There are at least three 
possible explanations for this apparent discrepancy. First, the partially purified 
native IFN~' could have been contaminated with a factor suppressing macrophage 
oxidative metabolism. Such a suppressive factor has been observed in the culture 
medium of murine lymphoid cells (46), and inhibitors of IFN antiviral activity 
are reportedly produced by stimulated lymphocytes (47).  The ability of mono- 
clonal antibody GIF-1  to neutralize native IFN~, without neutralizing recombi- 
nant  IFN'y  made it  possible  to  perform mixing experiments,  in  which native 
IFN3, preparations plus antibody GIF-1  were added to recombinant IFN%  No 684  INTERFERON-'r AS  MACROPHAGE-ACTIVATING FACTOR 
suppression  of the  macrophage-activating effect of the  latter  was  observed. 
However,  a  suppressive  factor  seemed  to  be  present  in  the  unpurified  LK 
preparations when they were used at high concentrations. The nature of such a 
suppressive factor and its possible role in anergic states warrant further study. 
A second possible explanation for the relative potency of recombinant IFN3, 
is that there could be a costimulator contaminating it, such as bacterial LPS (48). 
However,  in  mixing  experiments,  no  costimulator  activity  could  be  demon- 
strated.  Furthermore, we have not been able to  enhance human macrophage 
H202 release with LPS, using the same culture conditions as in the present work 
(C.  Nathan,  unpublished observations).  Finally,  no  LPS  was detectable in  the 
purified  recombinant  IFNy  by  the  limulus  amoebocyte  lysate  test  (personal 
communication, Dr.  C.  Sevastopoulos)  (limit of detection,  0.05  ng/ml).  This 
preparation  was effective after a  dilution of more than  10%fold.  Effectiveness 
after such dilution  virtually rules out a  contribution  by traces of LPS  in  the 
IFN% or by any other minor contaminant. 
Thus, a third possibility must be considered, that one molecule of recombinant 
IFN~,  may either have more potent MAF and/or less potent antiviral activity 
than one molecule of native IFNy, perhaps because of differences in posttransla- 
tional  modifications.  In  fact,  on  a  protein  basis,  SEA-IFNy and  recombinant 
1FN3'  had similar MAF activity. There is precedent for variations in ratios of 
different IFN effects when comparing natural and recombinant IFNs (49).  The 
reasons for these variations are not well understood. 
There have been almost no previous reports on the effects of IFN on macro- 
phage oxidative metabolism. Boraschi et al.  (50) reported that  IFN/3  inhibited 
the superoxide-releasing capacity of mouse peritoneal macrophages. However, 
pure IFN/3 was not used. It will be of interest to determine the relation between 
the  inhibitory  activity  in  that  study  and  the  factor  suppressing  macrophage 
oxidative metabolism that was detected in medium conditioned by a variety of 
cell types, including fibroblasts  (46).  In  contrast,  numerous reports have sug- 
gested that IFN may enhance antimicrobial activity of a variety of cells against 
pathogens other than viruses, including T. gondii (51-54), malaria (55), Rickettsia 
(56), shigellae (57), salmonellae (58), staphylococci (59), and mycobacteria (60). 
The  capacity of host  lymphocytes to  secrete IFNy  mounts  in  parallel  with 
other manifestations of delayed-type hypersensitivity and cell-mediated immunity 
(34, 39, 61, 62). This is consistent with the evidence presented here in support 
of the hypothesis that  IFNy mediates macrophage activation during the latter 
responses. Thus it seems appropriate  to ask whether provision of IFNy might 
favorably  affect  the  course  of diseases  in  which  persistent  parasitization  of 
macrophages is a prominent feature. These include some of the most prevalent 
chronic infections, such as tuberculosis, lepromatous leprosy, and leishmaniasis. 
Summary 
Human  blood  mononuclear leukocytes stimulated with  toxoplasma antigen, 
concanavalin  A,  mezerein plus  lentil  lectin,  or  staphylococcal enterotoxin  A 
secreted a  factor  (macrophage-activating factor,  or  MAF)  that  enhanced the 
capacity of human macrophages to release H~O2 and to kill  toxoplasmas. The 
same lymphoid supernatants contained IFN~ but not IFNa or IFNB. The MAr NATHAN  ET  AL.  685 
activity of six of seven unfractionated supernatants was completely eliminated by 
a  monoclonal  antibody  that  neutralizes  IFN%  and  MAF  in  the  remaining 
supernatant  was almost completely neutralized.  Native IFN3' partially purified 
by two independent  protocols to specific activities of 1 x  106 and  107  U/rag 
protein was enriched in MAF activity at least as much as in antiviral activity. The 
capacity of macrophages  to secrete  HzOu after incubation  in partially  purified 
native IFN3, (mean peak stimulation,  8.8-fold) was greater than with unpurified 
]ymphokines (3.8-fold) and sometimes equaled or exceeded the capacity of freshly 
harvested  monocytes. The  MAF activity of the  partially  purified  native  IFN~, 
preparations  was abolished by monoclonal  anti-IFN3,.  Finally,  IFN3, of >99% 
estimated  purity  was  isolated  (at  Genentech,  Inc.)  from  bacteria  transformed 
with the cloned human gene for this lymphokine. Recombinant IFN3, had potent 
MAF activity,  stimulating  the  peroxide-releasing  capacity  of macrophages  an 
average of 19.8-fold at peak response and  enhancing  their  ability to kill  toxo- 
plasmas  from  2.6  +  1.3%  for  untreated  cells to  54  +  0.4%  for  treated  cells. 
Attainment  of  50%  of the  maximal  elevation  in  peroxide-releasing  capacity 
required a geometric mean concentration of 0.1 antiviral  U/m] of recombinant 
IFN3,,  which  is  estimated  to  be  -~6  picomolar  for this  preparation.  Peroxide 
secretory capacity and  toxoplasmacidal  activity of macrophages  peaked  2-4  d 
after exposure to IFN3,.  Peroxide-secretory capacity remained elevated during 
at least 6 d  of continuous exposure, but the effect of IFN3, was reversed within 
about 3 d of its removal. Activation was usually but not invariably accompanied 
by  characteristic  changes  in  cell  morphology.  Thus,  IFN3,  activates  human 
macrophage oxidative metabolism and antimicrobial activity, and appeared to be 
the only factor consistently capable of doing so in the diverse LK preparations 
tested. 
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